Seminars in Ultrasound, CT and MRI
Volume 30, Issue 4 , Pages 359-366 , August 2009

Computed Tomography in Metastatic Renal Cell Carcinoma

  • Nyree Griffin, MD, MRCS, FRCR

      Affiliations

    • Department of Radiology, Guy's and St. Thomas' Hospital, London, UK
    • Corresponding Author InformationAddress reprint requests to Nyree Griffin, MD, St. Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK
    • ,
  • Lee Alexander Grant, BA (Oxon), MRCS, FRCR

      Affiliations

    • Department of Radiology, Chelsea and Westminster Hospital, London, UK
    • ,
  • Nishat Bharwani, BSc (Hons), MRCP, FRCR

      Affiliations

    • Department of Radiology, Barts and The London NHS Trust, London, UK
    • ,
  • S. Aslam Sohaib, MRCP, FRCR

      Affiliations

    • Department of Radiology, Royal Marsden Hospital, London, UK

References 

  1. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma: A clinical and pathologic study of 309 cases. Cancer. 1971;28:1165–1177
  2. Friedel G, Hürtgen M, Penzenstadler M, et al. Resection of pulmonary metastases from renal cell carcinoma. Anticancer Res. 1999;19:1593–1596
  3. Han KR, Pantuck AJ, Bui MH, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314–319
  4. In:  Ries LAG,  Melbert D,  Krapcho M, et al. editor. SEER cancer statistics review (National Cancer Institute). 1975-2005;http://seer.cancer.gov/csr/1975_2005
  5. Sandock DS, Seftel AD, Resnick MI. A new protocol for the follow up of renal cell carcinoma based on pathological stage. J Urol. 1995;154:28–31
  6. Chae EJ, Kim JK, Kim SH, et al. Renal cell carcinoma: Analysis of postoperative recurrence patterns. Radiology. 2005;234:189–196
  7. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655–663
  8. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11:71–77
  9. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: An experience of 405 cases. Am J Surg Pathol. 2002;26:281–291
  10. Snow RM, Schellhammer PF. Spontaneous regression of metastatic renal cell carcinoma. Urology. 1982;20:177–181
  11. Renshaw AA, Richie JP. Subtypes of renal cell carcinoma: Different onset and sites of metastatic disease. Am J Clin Pathol. 1999;111:539–543
  12. Hoffmann NE, Gillett MD, Cheville JC, et al. Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol. 2008;179:474–477
  13. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract LBA3]. J Clin Oncol. 2006;24:18S
  14. Hudes G, Carducci M, Tomczak P, et al. A phase 3 randomised, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line poor-risk patients with advanced renal cell carcinoma (adv RCC) [abstract LBA4]. J Clin Oncol. 2006;24:18S
  15. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the ref kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract 4510]. J Clin Oncol. 2005;23:380s
  16. Escudier BJ, Koralewski P, Pluzanska A, et al. A randomised controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol. 2007;25:18s
  17. Escudier B. Advanced renal cell carcinoma: Current and emerging management strategies. Drugs. 2007;67:1257–1264
  18. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–1659
  19. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial. Lancet. 2001;358:966–970
  20. Thyavihally YB, Mahantshetty U, Chamarajanagar RS, et al. Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol. 2005;3:48
  21. Levy DA, Slaton JW, Swanson DA, et al. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol. 1998;159:1163–1167
  22. Ljungberg B, Hanbury DC, Kuczyk MA, et al. European Association of Urology Guideline Group for renal cell carcinoma (Renal cell carcinoma guideline). Eur Urol. 2007;51:1502–1510
  23. Lim DJ, Carter MF. Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol. 1993;150:1112–1114
  24. Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843–852
  25. Ljungberg B, Alamdari FI, Rasmuson T, et al. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405–411
  26. Saidi JA, Newhouse JH, Sawczuk IS. Radiologic follow-up of patients with T1-3a, b, c or T4N+ M0 renal cell carcinoma after radical nephrectomy. Urology. 1998;52:1000–1003
  27. Uzzo RG, Novick AC, et al. Surveillance strategies following surgery for renal cell carcinoma. In:  Belldegrun AS,  Ritchie AW,  Figlin RA, et al. editor. Renal and Adrenal Tumors: Biology and Management. New York, NY: Oxford University Press; 2003;p. 324–330
  28. Stephenson AJ, Chetner MP, Rourke K, et al. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol. 2004;172:58–62
  29. Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc. 2000;75:1236–1242
  30. Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol. 2007;51:1490–1501
  31. Breda A, Konijeti R, Lam JS. Patterns of recurrence and surveillance strategies for renal cell carcinoma following surgical resection. Exp Rev Anticancer Ther. 2007;7:847–862
  32. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–1657
  33. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer. 2003;98:2566–2575
  34. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J Urol. 2002;168:2395–2400
  35. Frank I, Blute ML, Cheville JC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003;170:2225–2232
  36. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. J Urol. 2005;174:1759–1763
  37. Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88:348–353
  38. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–2540
  39. Cozzoli A, Milano S, Cancarini G, et al. Surgery of lung metastases in renal cell carcinoma. Br J Urol. 1995;75:445–447
  40. Shiono S, Yoshida J, Nishimura M. Late pulmonary metastasis of renal cell carcinoma resected 25 years after nephrectomy. Jpn J Clin Oncol. 2004;34:46–49
  41. Piltz S, Meimarakis G, Wichmann MW, et al. Long-term results after pulmonary resection of renal cell carcinoma. Ann Thorac Surg. 2002;73:1082–1087
  42. Kamiyoshihara M, Ibe T. Pleural metastases from renal cell carcinoma 16 years after resection. J Clin Oncol. 2007;25:4009–4011
  43. Itano NB, Blute ML, Spotts B, et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164:322–325
  44. Scatarige JC, Sheth S, Corl FM, et al. Patterns of recurrence in renal cell carcinoma: Manifestations on helical CT. AJR Am J Roentgenol. 2001;177:653–658
  45. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, et al. Patterns of failure following surgical resection of renal cell carcinoma: Implications for adjuvant local and systemic therapy. J Clin Oncol. 1994;12:206–212
  46. Sheth S, Scatarige JC, Horton KM, et al. Current concepts in the diagnosis and management of renal cell carcinoma: Role of multidetector CT and three-dimensional CT. Radiographics [Spec. no.]. 2001;S237–S254
  47. Reznek RH. CT/MRI in staging renal cell carcinoma. Cancer Imaging. 2004;4(spec. no. A):S25–S32
  48. Kang DE, White RL, Zuger JH, et al. Clinical use of fluorodeoxyglucose F-18 positron emission tomography for detection of renal cell carcinoma. J Urol. 2004;171:1806–1809
  49. Bachor R, Kotzerke J, Gottfried HW, et al. Positron emission tomography in diagnosis of renal cell carcinoma. Urologe A. 1996;35:146–150
  50. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol. 2005;23:2813–2821
  51. Ritchie AW, Chisholm GD. The natural history of renal carcinoma. Semin Oncol. 1983;10:390–400
  52. Scatarige JC, Sheth S, Corl FM, et al. Patterns of recurrence in renal cell carcinoma (Manifestations on helical CT). AJR Am J Roentgenol. 2001;177:653–658
  53. Stauffer MH. Nephrogenic hepatomegaly. Gastroenterology. 1961;40:694
  54. Mechó S, Quiroga S, Cuéllar H, et al. Pancreatic metastasis of renal cell carcinoma: Multidetector CT findings. Abdom Imaging [Epub ahead of print]. 2008;
  55. Giannakopoulos X, Charalabopoulos K, Charalabopoulos A, et al. Ipsilateral adrenalectomy for renal cell carcinoma; mandatory standard procedure or overtreatment?. Exp Oncol. 2003;25:245–247
  56. Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: Role of ipsilateral adrenalectomy and definition of stage. Urology. 1997;49:28–31
  57. Gill IS, McClennan BL, Kerbl K, et al. Adrenal involvement from renal cell carcinoma: Predictive value of computerized tomography. J Urol. 1994;152:1082–1108
  58. Henriksson C, Geterud K, Aldenborg F, et al. Bilateral asynchronous renal cell carcinoma (Computed tomography of the contralateral kidney 10-43 years after nephrectomy). Eur Urol. 1992;22:209
  59. Roviello F, Caruso S, Moscovita Falzarano S, et al. Small bowel metastases from renal cell carcinoma: A rare cause of intestinal intussusception. J Nephrol. 2006;19:234–238
  60. Tartar VM, Heiken JP, McClennan BL. Renal cell carcinoma presenting with diffuse peritoneal metastases: CT findings. J Comput Assist Tomogr. 1991;15:450–453
  61. Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J Urol. 2000;164:1505–1508
  62. Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: Presentation, recurrence and survival. Cancer. 2008;113:1641–1648
  63. Sheehan JP, Sun MH, Kondziolka D, et al. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: Long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg. 2003;98:342–349
  64. Iesalnieks I, Winter H, Bareck E. Thyroid metastases of renal cell carcinoma: Clinical course in 45 patients undergoing surgery (Assessment of factors affecting patients' survival). Thyroidology. 2008;18:615–624
  65. Kundu S. Eynon-Lewis NJ, Radcliffe GJ: Extensive metastatic renal cell carcinoma presenting as facial nerve palsy. J Laryngol Otol. 2001;115:488–490
  66. Kao C-C, Tang S-H, Wu S-T, et al. Abdominal subcutaneous metastasis from sarcomatoid renal cell carcinoma. J Med Sci. 2008;29:205–208
  67. Aridogan IA, Satar N, Doran F, et al. Scrotal skin metastases of renal cell carcinoma (A case report). Acta Chir Belgica. 2004;104:599–600
  68. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247
  69. Miller AB. Reporting results of cancer treatment. Cancer. 1981;47:207–2141
  70. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada). J Natl Cancer Inst. 2000;92:205–216
  71. Therasse P, Eisenhauer EA, Verweij J, et al. A review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031–1039
  72. Choi H, Charnsangavej C, de Castro FS, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings. AJR. 2004;183:1619–1628
  73. Flaherty KT, Rosen MA, Heitjan DF, et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther. 2008;7:496–501
  74. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008;26:4572–4578

 Work originated from Royal Marsden Hospital, London.

PII: S0887-2171(09)00025-0

doi: 10.1053/j.sult.2009.03.007

Seminars in Ultrasound, CT and MRI
Volume 30, Issue 4 , Pages 359-366 , August 2009

Article Tools

* Image Usage & Resolution